Pretargeting (imaging)

Pretargeting is a method used in medical imaging to increase the specificity of radiolabeled agents. This method is particularly useful in cancer imaging and therapy, where it is crucial to deliver the radiolabeled agent to the tumor cells while minimizing exposure to healthy tissues.

Overview

Pretargeting involves two steps. First, a biomolecule that can bind to the target cells is administered. This biomolecule is typically an antibody or an antibody fragment, and it is modified to carry a small molecule that can bind to a radiolabeled agent. After the biomolecule has had time to bind to the target cells and any unbound biomolecule has been cleared from the body, the radiolabeled agent is administered. This agent is designed to bind to the small molecule on the biomolecule, thereby delivering the radioactivity to the target cells.

Advantages

Pretargeting has several advantages over traditional methods of radiolabeling. Because the radiolabeled agent is administered after the biomolecule has had time to bind to the target cells and any unbound biomolecule has been cleared from the body, there is less exposure of healthy tissues to radioactivity. This can reduce side effects and improve the quality of the images obtained. In addition, because the radiolabeled agent is small, it can penetrate tissues more effectively than a large biomolecule, potentially improving the delivery of the radioactivity to the target cells.

Applications

Pretargeting has been used in a variety of applications, including cancer imaging and therapy. For example, it has been used to deliver radiolabeled agents to tumor cells in patients with colorectal cancer, breast cancer, and lymphoma. It has also been used in preclinical studies to image and treat tumors in animal models.

See also

• Radiolabeling
• Medical imaging
• Cancer imaging
• Antibody

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia